title: The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
abstract: Based on the profound biological insights of the last years into the molecular pathogenesis of mantle cell lymphoma and the clinical introduction of new targeted drugs, with high efficacy and a good safety profile, the therapeutic scenario for this tumor has been shown to be thoroughly favourable. No longer characterized by a uniformly dismal prognosis, mantle cell lymphoma has been revealed as a spectrum of different diseases, ranging from very indolent cases to highly aggressive and refractory ones. Thus, there is an urgent need to adapt therapy to accommodate the diverse presentations of the disease. High-dose chemotherapy, followed by autologous stem cell transplantation is the current standard of care for younger patients, generally providing high responses and long survival rates, but hampered by acute and long-term toxicity. In addition, some patients may be overtreated, while others could benefit from targeted approaches, based on the new, molecular-directed compounds. Such a personalized treatment based on the specific characteristics of individual patients may be guided by validated prognostic tools, such as the Mantle Cell Lymphoma International Prognostic Index and the Ki-67 Proliferative Index, as well as by early predictors of treatment response, like minimal residual disease analysis. Moreover, mutation screening of distinctive genomic alterations may provide new, predictive biomarkers, with an additional impact on clinical practice. Only after tailoring treatment according to the clinical and biological heterogeneity of the disease the role of transplantation and modern therapeutic options will be redefined in mantle cell lymphoma.
authors.affiliation: Department of Medicine III, Hospital of the University LMU München, Germany martin.dreyling@med.uni-muenchen.de.
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy.
authors.forename: Simone
authors.initials: S
authors.lastname: Ferrero
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D018365:Neoplasm, Residual; D057285:Precision Medicine; D011379:Prognosis; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D054316:Biomarkers, Pharmacological
references.citation: Br J Haematol. 2012 Feb;156(3):346-53
references.pmid: 22145911
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3822-9
references.pmid: 19581539
references.citation: J Clin Oncol. 2016 Apr 20;34(12):1386-94
references.pmid: 26926679
references.citation: Ann Hematol. 2013 Nov;92(11):1503-11
references.pmid: 23737092
references.citation: Blood. 2008 Feb 15;111(4):2385-7
references.pmid: 18077791
references.citation: Leukemia. 2007 Apr;21(4):604-11
references.pmid: 17287850
references.citation: J Clin Oncol. 2013 Oct 10;31(29):3688-95
references.pmid: 24002500
references.citation: Leuk Lymphoma. 2009 May;50(5):716-22
references.pmid: 19347767
references.citation: Ann Oncol. 2014 Sep;25 Suppl 3:iii83-92
references.pmid: 25210087
references.citation: Leuk Lymphoma. 2008 Jun;49(6):1017-8
references.pmid: 18452075
references.citation: Leuk Lymphoma. 2014 May;55(5):1206-8
references.pmid: 23876100
references.citation: N Engl J Med. 2012 Aug 9;367(6):520-31
references.pmid: 22873532
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6101-8
references.pmid: 19917845
references.citation: Ann Oncol. 2013 Jun;24(6):1587-93
references.pmid: 23504948
references.citation: N Engl J Med. 2015 Mar 5;372(10):944-53
references.pmid: 25738670
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7013-23
references.pmid: 16145068
references.citation: Blood. 2014 May 29;123(22):3398-405
references.pmid: 24615778
references.citation: J Clin Oncol. 2009 Feb 1;27(4):511-8
references.pmid: 19075279
references.citation: N Engl J Med. 2013 Aug 8;369(6):507-16
references.pmid: 23782157
references.citation: Br J Haematol. 2014 Jul;166(1):98-108
references.pmid: 24684350
references.citation: Blood. 2012 May 17;119(20):4597-607
references.pmid: 22383795
references.citation: Leukemia. 2015 Feb;29(2):464-73
references.pmid: 25034148
references.citation: Blood. 2008 Jan 15;111(2):558-65
references.pmid: 17962512
references.citation: Ann Hematol. 2014 Feb;93(2):233-42
references.pmid: 23949376
references.citation: Blood. 2010 Feb 25;115(8):1530-3
references.pmid: 20032504
references.citation: Br J Haematol. 2012 Oct;159(2):154-63
references.pmid: 22881386
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4867-74
references.pmid: 17001068
references.citation: Blood. 2008 Oct 1;112(7):2687-93
references.pmid: 18625886
references.citation: Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18250-5
references.pmid: 24145436
references.citation: Blood. 2013 Jan 3;121(1):48-53
references.pmid: 22718839
references.citation: Cancer Res. 2012 Oct 15;72(20):5307-16
references.pmid: 22915760
references.citation: Bone Marrow Transplant. 1998 Oct;22(7):645-50
references.pmid: 9818691
references.citation: Blood. 2011 Jan 6;117(1):26-38
references.pmid: 20940415
references.citation: Genes Chromosomes Cancer. 2014 Jan;53(1):106-16
references.pmid: 24249260
references.citation: Mod Pathol. 2015 Nov;28(11):1435-47
references.pmid: 26360498
references.citation: Blood. 2012 Mar 1;119(9):1963-71
references.pmid: 22210878
references.citation: J Clin Oncol. 2011 Mar 1;29(7):814-24
references.pmid: 21189387
references.citation: Haematologica. 2012 Mar;97(3):416-22
references.pmid: 22058200
references.citation: Clin Cancer Res. 2011 May 15;17(10):3388-97
references.pmid: 21447728
references.citation: J Clin Oncol. 2015 May 20;33(15):1703-6
references.pmid: 25897155
references.citation: Leukemia. 2002 Apr;16(4):587-93
references.pmid: 11960337
references.citation: J Clin Oncol. 1998 May;16(5):1922-30
references.pmid: 9586911
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1209-13
references.pmid: 19188674
references.citation: J Clin Oncol. 2013 Aug 10;31(23):2912-9
references.pmid: 23835718
references.citation: Science. 2008 Aug 15;321(5891):974-7
references.pmid: 18703743
references.citation: J Clin Oncol. 1998 Jan;16(1):13-8
references.pmid: 9440717
references.citation: J Clin Oncol. 2005 Feb 1;23(4):676-84
references.pmid: 15613699
references.citation: Leukemia. 2014 Nov;28(11):2117-30
references.pmid: 24854989
references.citation: Br J Haematol. 2009 Feb;144(4):524-30
references.pmid: 19036081
references.citation: J Hematop. 2009 Jul;2(2):103-11
references.pmid: 19669190
references.citation: J Clin Oncol. 2010 Jan 20;28(3):418-23
references.pmid: 20008633
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1460-8
references.pmid: 15084619
references.citation: J Clin Oncol. 2005 Feb 1;23(4):667-75
references.pmid: 15613697
references.citation: Cancer Res. 2010 Feb 15;70(4):1408-18
references.pmid: 20124476
references.citation: J Clin Oncol. 2014 May 1;32(13):1338-46
references.pmid: 24687837
references.citation: J Clin Oncol. 1998 Dec;16(12):3803-9
references.pmid: 9850025
references.citation: Blood. 2006 Mar 15;107(6):2271-8
references.pmid: 16332971
references.citation: Clin Cancer Res. 2014 Oct 15;20(20):5194-206
references.pmid: 25320369
references.citation: Blood. 2012 May 3;119(18):4215-23
references.pmid: 22431568
references.citation: Br J Haematol. 2012 Aug;158(3):355-62
references.pmid: 22640180
references.citation: Leuk Lymphoma. 2000 Sep;39(1-2):77-85
references.pmid: 10975386
references.citation: Blood. 2010 Apr 22;115(16):3215-23
references.pmid: 20032498
references.citation: Blood. 2014 May 8;123(19):2953-9
references.pmid: 24652994
references.citation: Blood. 2014 Aug 21;124(8):1288-95
references.pmid: 24859361
references.citation: Leukemia. 2015 Aug;29(8):1695-701
references.pmid: 25765545
references.citation: Blood. 2005 Apr 1;105(7):2677-84
references.pmid: 15591112
references.citation: Br J Haematol. 2010 Jul;150(2):200-8
references.pmid: 20528872
references.citation: Lancet Oncol. 2012 Jul;13(7):716-23
references.pmid: 22677155
references.citation: Clin Cancer Res. 2011 Apr 15;17(8):2493-501
references.pmid: 21346146
references.citation: Br J Haematol. 2003 Mar;120(5):793-800
references.pmid: 12614212
references.citation: Blood. 2011 Mar 10;117(10):2807-12
references.pmid: 21239695
references.citation: Lancet Oncol. 2015 Jun;16(6):704-15
references.pmid: 25925619
references.citation: Ann Oncol. 2009 Mar;20(3):520-5
references.pmid: 19074748
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4365-70
references.pmid: 19652064
references.citation: Blood. 2003 Jul 15;102(2):749-55
references.pmid: 12663455
references.citation: Blood. 2015 Jul 30;126(5):604-11
references.pmid: 26022239
references.citation: Lancet Oncol. 2011 Apr;12(4):361-8
references.pmid: 21440503
references.citation: Blood. 1997 Nov 15;90(10):4212-21
references.pmid: 9354694
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1984-92
references.pmid: 15668467
references.citation: Blood. 2015 Apr 23;125(17):2669-77
references.pmid: 25736311
references.citation: Ann Oncol. 2015 Jun;26(6):1175-1179
references.pmid: 25712454
references.citation: J Clin Invest. 2012 Oct;122(10):3416-23
references.pmid: 23023712
references.citation: J Clin Oncol. 2011 Feb 20;29(6):690-7
references.pmid: 21189393
references.citation: Ann Oncol. 2011 Jul;22(7):1622-1627
references.pmid: 21228334
references.citation: Blood. 2004 Nov 15;104(10):3064-71
references.pmid: 15284112
references.citation: J Clin Oncol. 2008 Oct 20;26(30):4952-7
references.pmid: 18606983
references.citation: J Clin Oncol. 2013 Apr 10;31(11):1442-9
references.pmid: 23401442